scholarly journals Walking Speed: Japanese Data in Chronic Liver Diseases

2020 ◽  
Vol 9 (1) ◽  
pp. 166
Author(s):  
Hiroki Nishikawa ◽  
Hirayuki Enomoto ◽  
Kazunori Yoh ◽  
Yoshinori Iwata ◽  
Yoshiyuki Sakai ◽  
...  
Keyword(s):  
Liver Diseases ◽  
Walking Speed ◽  
Handgrip Strength ◽  
Extracellular Fluid ◽  
Chronic Liver ◽  
P Value ◽  
Extracellular Water ◽  
Chronic Liver Diseases ◽  
Total Body ◽  
The Impact

We aim to clarify the impact of walking speed (WS) and analyze factors linked to WS decline in patients with chronic liver diseases (CLDs, 165 males and 191 females, 137 liver cirrhosis patients). The WS decline is defined as <0.8 m/second (m/s), referring to the guidelines. The median (range) WS was 1.3 m/s (0.2–2.02 m/s). There were 17 patients with WS < 0.8 m/s (4.8%). The WS value was significantly correlated with the handgrip strength value both in males (r2 = 0.252, p < 0.0001) and females (r2 = 0.256, p < 0.0001). In the multivariate analysis of factors associated with WS decline, only the extracellular water (ECW) to total body water (TBW) ratio using bioimpedance analysis was an independent predictor (p = 0.0398). Extracellular fluid excess was categorized as follows: normal condition (ECW to TBW ratio < 0.390), mild overhydrated condition (ECW to TBW ratio 0.390–0.399), and moderate to severe overhydrated condition (ECW to TBW ratio ≥ 0.400). The WS value was well stratified according to the ECW to TBW ratio (normal vs. mild, p = 0.0001; mild vs. moderate to severe, p < 0.0001; normal vs. moderate to severe, p < 0.0001; overall p-value < 0.0001). In conclusion, the ECW to TBW ratio can be closely linked to WS decline in CLD patients.

Reduced Handgrip Strength Predicts Poorer Survival in Chronic Liver Diseases: A Large Multi‐Center Study in Japan

2021 ◽  
Author(s):  
Hiroki Nishikawa ◽  
Makoto Shiraki ◽  
Akira Hiramatsu ◽  
Nagisa Hara ◽  
Kyoji Moriya ◽  
...  
Keyword(s):  
Liver Diseases ◽  
Handgrip Strength ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Multi Center Study ◽  
Center Study

The Impact of p53 Mutations on the Course of Hepatitis B or C-related Chronic Liver Diseases in Taiwan

2009 ◽  
Vol 104 ◽  
pp. S148
Author(s):  
Yone-Han Mah ◽  
Ching-Sheng Hsu ◽  
Chen-Hua Liu ◽  
Chun-Jen Liu ◽  
Ming-Yang Lai ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Liver Diseases ◽  
Chronic Liver ◽  
P53 Mutations ◽  
Chronic Liver Diseases ◽  
The Impact

scholarly journals Predictors of Quality of Life after Liver Transplant

2019 ◽  
Vol 2 (1) ◽  
Author(s):  
Joey Wu ◽  
Archita Desai, MD
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
General Population ◽  
Liver Transplant ◽  
Liver Diseases ◽  
Chronic Liver ◽  
University Hospital ◽  
Chronic Liver Diseases ◽  
The Impact

Background and Hypothesis: The impact of chronic liver diseases on patients and their family member is often understated and understudied. Chronic liver diseases can sometimes progress to a need for Liver transplant (LT). While recent studies have described quality of life (QOL) at different stages of liver disease, the impact of the patient’s QOL in LT survivors has not been examined. The importance of studying QOL in patients is due to its effect on the survivorship of LT recipients. We hypothesize that QOL in LT patients is lower than the general population. Our aim was to describe predictors of QOL in a well-described cohort of LT patients. Methods: Patients were enrolled at the Digestive and Liver Disease Liver clinic at Indiana University Hospital. All patients over the age of 18 were approached, if patients consented to the study, they were then enrolled during their liver follow up visit. The PROMIS survey was administered on an iPad and completed during the clinic visit. Survey were then scored and analyzed. Results: The T-scores for post liver transplant patients are lower in physical function, anxiety and depression, but higher in general life satisfaction compared to the general population. LT recipients have similar T-scores in Fatigue, Sleep disturbance, ability to participate in social activities, and pain interference compared to the general population. Conclusion and Potential Impact: Previous diagnosis of PBC, HCC, diagnosis of depression, household income, insurance status, Charlson Comorbid Index and number of non-transplant related medications have the highest association with quality of life. Further enrollment is needed to increase the power of the study. However, this can inform physicians the importance to taking these factors in to consideration in order to improve the QOL in LT recipients.

scholarly journals Serum Zinc Concentration and Sarcopenia: A Close Linkage in Chronic Liver Diseases

2019 ◽  
Vol 8 (3) ◽  
pp. 336 ◽  
Author(s):  
Hiroki Nishikawa ◽  
Hirayuki Enomoto ◽  
Kazunori Yoh ◽  
Yoshinori Iwata ◽  
Yoshiyuki Sakai ◽  
...  
Keyword(s):  
Liver Diseases ◽  
Independent Predictor ◽  
Serum Zinc ◽  
Chronic Liver ◽  
Zn Deficiency ◽  
P Value ◽  
Chronic Liver Diseases ◽  
Baseline Serum ◽  
Zn Concentration ◽  
Serum Zn

We sought to investigate the influence of serum zinc (Zn) concentration on sarcopenia in chronic liver diseases (CLDs, n = 372, median age = 65 years, 147 liver cirrhosis (LC) cases (39.5%)). Sarcopenia was defined by low grip strength and low skeletal muscle mass. Study subjects were divided into the following three groups (High-, Intermediate-, and Low-Zn groups) based on the baseline serum Zn level. The impacts of serum Zn concentration on sarcopenia were examined. The median (interquartile range) serum Zn concentration for all cases was 72.85 (63.7, 81.45) μg/dL. The proportions of sarcopenia in the High-Zn, Intermediate-Zn, and Low-Zn groups were 10.75% (10/93), 11.23% (21/187), and 27.17% (25/92), respectively (P = 0.9046 (High vs. Intermediate), P = 0.0007 (Intermediate vs. Low), P = 0.0044 (High vs. Low), overall P value = 0.0009). The median serum Zn concentrations in patients with sarcopenia, pre-sarcopenia, and control were 66.35, 73.1 and 73.8 μg/dL, respectively (P = 0.0234 (sarcopenia vs. pre-sarcopenia), P = 0.2116 (pre-sarcopenia vs. control), P = 0.0002 (sarcopenia vs. control), overall P value = 0.0016). In the multivariate analyses of factors linked to the presence of sarcopenia, Low-Zn was an independent predictor for all cases (P = 0.0236) and LC cases (P = 0.0082). In conclusion, Zn deficiency can be an independent predictor for sarcopenia in patients with CLDs.

scholarly journals Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma

Nutrients ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1576 ◽  
Author(s):  
Daisuke Uchida ◽  
Akinobu Takaki ◽  
Atsushi Oyama ◽  
Takuya Adachi ◽  
Nozomu Wada ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Viral Hepatitis ◽  
Liver Diseases ◽  
Chronic Viral Hepatitis ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Anti Cancer ◽  
The Impact

Chronic viral hepatitis B and C and non-alcoholic fatty liver disease (NAFLD) have been widely acknowledged to be the leading causes of liver cirrhosis and hepatocellular carcinoma. As anti-viral treatment progresses, the impact of NAFLD is increasing. NAFLD can coexist with chronic viral hepatitis and exacerbate its progression. Oxidative stress has been recognized as a chronic liver disease progression-related and cancer-initiating stress response. However, there are still many unresolved issues concerning oxidative stress, such as the correlation between the natural history of the disease and promising treatment protocols. Recent findings indicate that oxidative stress is also an anti-cancer response that is necessary to kill cancer cells. Oxidative stress might therefore be a cancer-initiating response that should be down regulated in the pre-cancerous stage in patients with risk factors for cancer, while it is an anti-cancer cell response that should not be down regulated in the post-cancerous stage, especially in patients using anti-cancer agents. Antioxidant nutrients should be administered carefully according to the patients’ disease status. In this review, we will highlight these paradoxical effects of oxidative stress in chronic liver diseases, pre- and post-carcinogenesis.

Modifications of Medical Care of Chronic Liver Diseases during COVID19 Pandemic: Necessity or Novelty?

2021 ◽  
Vol 20 ◽  
Author(s):  
Hanan Hamed Soliman ◽  
Mohamed H. Emara ◽  
Mahmoud Elkadeem ◽  
Sherief Abd-Elsalam
Keyword(s):  
Health Care ◽  
Medical Care ◽  
21St Century ◽  
Liver Diseases ◽  
Health Care Systems ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
The World ◽  
Care Systems ◽  
The Impact

: In the late 2019, coronavirus-2 (SARS-COV 2) infection emerged in Wuhan, China and spread to all countries making the first pandemic in 21st century. It seems that this infection will continue period which is long enough to obligate modifications in both life style and health care systems. Because chronic liver diseases (CLD) are prevalent all over the world, it is expected to manage patients with CLD and COVID-19. The aim of this review was to shade the light on the impact of COVID-19 pandemic on the management of patients with CLD and how to give medical care to CLD patients during COVID-19 pandemic.

scholarly journals Antioxidant preconditioning improves therapeutic outcomes of adipose tissue-derived mesenchymal stem cells through enhancing intrahepatic engraftment efficiency in a mouse liver fibrosis model

2020 ◽  
Author(s):  
Naishun Liao ◽  
Yingjun Shi ◽  
Yingchao Wang ◽  
Fangyu Liao ◽  
Bixing Zhao ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Liver Fibrosis ◽  
Liver Diseases ◽  
Histopathological Examination ◽  
Oxidative Injury ◽  
Chronic Liver ◽  
Therapeutic Effects ◽  
Chronic Liver Diseases ◽  
Therapeutic Outcomes ◽  
The Impact

Abstract Background: Although it has been pre-clinically suggested that adipose tissue-derived mesenchymal stem cell (ADSCs)-based therapy could effectively treat chronic liver diseases, the hepatic engraftment of ADSCs is still extremely low, which severely limits their long-term efficacy for chronic liver diseases. This study was designed to investigate the impact of antioxidant preconditioning on hepatic engraftment efficiency and therapeutic outcomes of ADSC transplantation in liver fibrotic mice. Methods: Liver fibrosis model was established by using intraperitoneal injection of carbon tetrachloride (CCl 4 ) in the male C57BL/6 mice. Subsequently, the ADSCs with or without antioxidant pretreatment (including melatonin and reduced glutathione (GSH)) were administrated into fibrotic mice via tail vein injection. Afterwards, the ADSC transplantation efficiency was analyzed by ex vivo imaging, and the liver functions were assessed by biochemical analysis and histopathological examination, respectively. Additionally, a typical hydrogen peroxide (H 2 O 2 )-induced cell injury model was applied to mimic the cell oxidative injury to further investigate the protective effects of antioxidant preconditioning on cell migration, proliferation and apoptosis of ADSCs. Results: Our data showed that antioxidant preconditioning could enhance the therapeutic effects of ADSCs on liver function recovery by reducing the level of AST, ALT and TBIL, as well as the content of hepatic hydroxyproline and fibrotic area in liver tissues. Particularly, we also found that antioxidant preconditioning could enhance hepatic engraftment efficiency of ADSCs in liver fibrosis model through inhibiting oxidative injury. Conclusions: Antioxidant preconditioning could effectively improve therapeutic effects of ADSC transplantation for liver fibrosis through enhancing intrahepatic engraftment efficiency by reducing oxidative injuries. These findings might provide a practical strategy for enhancing ADSC transplantation and therapeutic efficiency.

scholarly journals Serum Zinc Level Is Associated with Frailty in Chronic Liver Diseases

2020 ◽  
Vol 9 (5) ◽  
pp. 1570 ◽  
Author(s):  
Hiroki Nishikawa ◽  
Kazunori Yoh ◽  
Hirayuki Enomoto ◽  
Yoshinori Iwata ◽  
Yoshiyuki Sakai ◽  
...  
Keyword(s):  
Liver Diseases ◽  
Serum Zinc ◽  
Body Weight Loss ◽  
Zinc Level ◽  
Clinical Syndrome ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Serum Zn ◽  
Total Body ◽  
Frailty Score

We sought to examine the serum zinc (Zn) level and frailty in patients with chronic liver diseases (CLDs, n = 285, 107 liver cirrhosis cases, median age = 66 years). Frailty was defined as a clinical syndrome in which three or more of the following criteria were met (frailty score 3, 4, or 5): unintentional body weight loss, self-reported exhaustion, muscle weakness (grip strength: <26 kg in men and <18 kg in women), slow walking speed (<1.0 m/s), and low physical activity. Robust (frailty score 0), prefrail (frailty score 1 or 2), and frailty were found in 90 (31.6%), 157 (55.1%), and 38 (13.3%), respectively. The median serum Zn levels in patients with frailty, prefrailty, and robust were 59.7 μg/dL, 72.8 μg/dL, and 76.9 μg/dL, respectively (p-values: frailty vs. prefrail, p < 0.0001; prefrail vs. robust, p = 0.0063; frailty vs. robust, p < 0.0001; overall p < 0.0001). For all cases, variables with absolute values of correlation coefficient with frailty score (0–5) ≥ 0.3 were age (rs = 0.3570, p < 0.0001), serum albumin (rs = −0.3212, p < 0.0001), extracellular water to total body water ratio using bioimpedance analysis (rs = 0.4386, p < 0.0001), and serum Zn level (rs = −0.3406, p < 0.0001). In conclusion, decreased serum Zn level in patients with CLDs can be closely associated with the presence of frailty.

Sign in / Sign up

Export Citation Format

Share Document